22 04 21 hongkong

CS MEDICA has been approved by Hong Kong Custom and has received a trial order for the Hong Kong market

CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has been approved by the Hong Kong customs and is now able to sell its CANNASEN® CBD products in Hong Kong.  The Company has just received its first trial order from its sponsor/importer in Hong Kong.

CS MEDICA has just received the final approval from Hong Kong customs, the Drug Registration Office, confirming that the CANNASEN® CBD product line can be sold to Hong Kong.  With reference to the less than 1PPB THC certificates showing zero traces of THC, the CANNASEN® CBD product line can be sold in Hong Kong without further applications or registrations.

According to the RAMS regulative system classifications and the Medial Device Control Office (MDCO); the CANNASEN® CBD product line will be classified under Medical Device class I.  This sponsor’s partner (distributor) has good access and experience in the following countries in the Asian markets, with cannabis products legalized, Hong Kong, China, Thailand, Malaysia, and Japan.

ISO certificates, declarations of conformity, the less than 1PPB THC certificates, Free sales certificates together with the Clinical trials has now been sent to the sponsor and their distributor partner.

CS MEDICA has received a small trial order from the sponsor/importer which together with their distributor partner will ensure free passage all the way to the sales channels and end-user in Hong Kong.  The trial order covers all products, and a total of 3.300 units of the following products:

  • Cannasen®CBD Arthritis Gel
  • Cannasen®CBD Psoriasis Gel
  • Cannasen®CBD Anti-Hair loss serum
  • Cannasen®CBD Pain Patch
  • Cannasen®CBD Protective Nasal Gel
  • Cannasen®CBD PSOR + ATOPIC Lotio
  • Cannasen®CBD Wound Gel

With CS MEDICA now complying with the very strict requirements of Dangerous Drugs Ordinance (DDO) and now approved by the Hong Kong customs the Company can later register and get the products approved for sales in the other countries in Asia, with cannabis products legalized (Thailand, Malaysia, and Japan).

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.